The Alzheimer’s therapeutic Lecanemab attenuates Aβ pathology by inducing an amyloid-clearing program in microglia
Top Cited Papers
Open Access
- 24 November 2025
- journal article
- research article
- Published by Springer Nature in Nature Neuroscience
- Vol. 29 (1) , 100-110
Abstract
Controversies over anti-amyloid immunotherapies underscore the need to elucidate their mechanisms of action. Here we demonstrate that Lecanemab, a leading anti-β-amyloid (Aβ) antibody, mediates amyloid clearance by activating microglial effector functions. Using a human microglia xenograft mouse model, we show that Lecanemab significantly reduces Aβ pathology and associated neuritic damage, while neither fragment crystallizable (Fc)-silenced Lecanemab nor microglia deficiency elicits this effect despite intact plaque binding. Single-cell RNA sequencing and spatial transcriptomic analyses reveal that Lecanemab induces a focused transcriptional program that enhances phagocytosis, lysosomal degradation, metabolic reprogramming, interferon γ genes and antigen presentation. Finally, we identify SPP1 /osteopontin as a major factor induced by Lecanemab treatment and demonstrate its role in promoting Aβ clearance. These findings highlight that effective amyloid removal depends on the engagement of microglia through the Fc fragment, providing critical insights for optimizing anti-amyloid therapies in Alzheimer’s disease.Keywords
This publication has 63 references indexed in Scilit:
- Lecanemab preferentially binds to smaller aggregates present at early Alzheimer's diseaseAlzheimer's & Dementia, 2025
- Microglia-astrocyte crosstalk in the amyloid plaque niche of an Alzheimer’s disease mouse model, as revealed by spatial transcriptomicsCell Reports, 2024
- Microglia maintain structural integrity during fetal brain morphogenesisCell, 2024
- hdWGCNA identifies co-expression networks in high-dimensional transcriptomics dataCell Reports Methods, 2023
- Secreted phosphoprotein 1 slows neurodegeneration and rescues visual function in mouse models of aging and glaucomaCell Reports, 2022
- Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's DiseaseNeurotherapeutics, 2022
- Integrated analysis of multimodal single-cell dataCell, 2021
- Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer’s DiseaseCell, 2020
- The Major Risk Factors for Alzheimer’s Disease: Age, Sex, and Genes Modulate the Microglia Response to Aβ PlaquesCell Reports, 2019
- DoubletFinder: Doublet Detection in Single-Cell RNA Sequencing Data Using Artificial Nearest NeighborsCell Systems, 2019